English   español  
Por favor, use este identificador para citar o enlazar a este item: http://hdl.handle.net/10261/125009
Título

The proteasome inhibitor bortezomib reduced cholesterol accumulation in fibroblasts from Niemann-Pick type C patients carrying missense mutations

AutorMacías-Vidal, Judit; Girós, Marisa; Guerrero, Martina; Gascón, Pere; Serratosa, Joan ; Bachs, Oriol; Coll, Josep
Palabras claveBortezomib
Missense mutations
Niemann-Pick type C disease
NPC1 protein
Proteasome inhibitors
Fecha de publicación21-ago-2014
EditorJohn Wiley & Sons
CitaciónThe Febs Journal 281(19): 4450-4466 (2014)
Resumen© 2014 FEBS. Niemann-Pick disease type C (NPC) is a lipid storage disorder mainly caused by mutations in the NPC1 gene. Approximately 60% of these mutations are missense changes that may induce reduced NPC1 protein levels by increased degradation via ubiquitin-proteasome. This is the case for the most prevalent worldwide mutation, p.Ile1061Thr, as well as for other three missense changes. In the present study, we analyzed the NPC1 levels in fibroblasts from eighteen NPC patients presenting missense mutations. We found that fourteen of these cells lines showed decreased levels of NPC1. Six of these cell lines were homozygous, whereas the other eight were associated with a frame shifting mutation. We focused our attention in the NPC homozygous samples and demonstrated that, in most of the cases, NPC1 reduction was a consequence of a decrease of its half-life. NPC cells were treated not only with the proteasome inhibitors carbobenzoxy-L-leucyl-L-leucyl-L-leucinal or N-acetyl-leucyl-leucylnorleucinal, both widely used as a research tools, but also with bortezomib, the first proteasome inhibitor to reach clinical applications, although it has never been used in NPC disease. We observed that, after treatment, the mutant NPC1 protein levels were partially recovered in most of the cell lines. Importantly, these mutant proteins partially recovered their activity and substantially reduced free cholesterol levels. These results suggest that by enhancing the NPC1 protein stability with the use of proteasome inhibitors, their functionality might be recovered and this might represent a therapeutical approach for future treatments of NPC disease resulting from specific missense mutations.
Versión del editorhttp://dx.doi.org/10.1111/febs.12954
URIhttp://hdl.handle.net/10261/125009
DOI10.1111/febs.12954
Identificadoresdoi: 10.1111/febs.12954
issn: 1742-4658
Aparece en las colecciones: (IIBB) Artículos
Ficheros en este ítem:
Fichero Descripción Tamaño Formato  
accesoRestringido.pdf15,38 kBAdobe PDFVista previa
Visualizar/Abrir
Mostrar el registro completo
 

Artículos relacionados:


NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.